IFNB1 and myeloid sarcoma: Once high titer NAbs to IFNβ have been established, they may persist for many years and thus render patients unsuitable for IFNβ treatment, which thanks to the arrival of new MS disease modifying treatments (DMTs) has become a less critical problem with time (17–19).